AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-06. Numbers and descriptions here follow the published literature rather than marketing material.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
== Effects of the Closure == Madera Community Hospital was the only hospital within a 30 mile radius, thus the closure caused 160,000 Madera residents to not have access to a local emergency room. Many people were faced with driving the 45 minutes to one of the neighboring towns or not receiving proper treatment. Unfortunately, this decision was already made for residents without access to a vehicle or public transportation. Other hospitals in the Central Valley were then stressed by the pressures of taking on all of the patients who would have previously been treated in Madera, which caused significant increases in emergency room wait times. Private ambulance companies from other counties pitched in to help take calls from Madera to transport residents to other hospitals such as Saint Agnes Medical Care (Fresno) and Community Regional Medical Center (Fresno). Not only were the patients redirected, 772 employees across the four locations were laid off when the hospital shuttered its doors.
== Biosynthesis and metabolism == Flavonoid biosynthesis in plants uses a phenylpropanoid metabolic pathway in which the amino acid phenylalanine is converted to 4-coumaroyl-CoA. This is combined with malonyl-CoA to yield a group of compounds called chalcones, which contain two phenyl rings. In the case of naringenin, the precursor is naringenin chalcone produced by the enzyme chalcone synthase. This can cyclise spontaneously but would provide racemic material. The enzyme chalcone isomerase constrains the reaction to give only the (S) isomer of the flavanone.
Cellular membrane disruption Chemical reaction with downstream effects Interaction with enzyme proteins Interaction with structural proteins Interaction with carrier proteins Interaction with ion channels Ligand binding to receptors: Hormone receptors Neuromodulator receptors Neurotransmitter receptors General anesthetics were once thought to work by disordering the neural membranes, thereby altering the Na+ influx. Antacids and chelating agents combine chemically in the body. Enzyme-substrate binding is a way to alter the production or metabolism of key endogenous chemicals, for example aspirin irreversibly inhibits the enzyme prostaglandin synthetase (cyclooxygenase) thereby preventing inflammatory response. Colchicine, a drug for gout, interferes with the function of the structural protein tubulin, while digitalis, a drug still used in heart failure, inhibits the activity of the carrier molecule, Na-K-ATPase pump. The widest class of drugs act as ligands that bind to receptors that determine cellular effects. Upon drug binding, receptors can elicit their normal action (agonist), blocked action (antagonist), or even action opposite to normal (inverse agonist). In principle, a pharmacologist would aim for a target plasma concentration of the drug for a desired level of response. In reality, there are many factors affecting this goal. Pharmacokinetic factors determine peak concentrations, and concentrations cannot be maintained with absolute consistency because of metabolic breakdown and excretory clearance.
== Presence in nonerythroid cells == Some nonerythroid cells (i.e., cells other than the red blood cell line) contain hemoglobin. In the brain, these include the A9 dopaminergic neurons in the substantia nigra, astrocytes in the cerebral cortex and hippocampus, and in all mature oligodendrocytes. It has been suggested that brain hemoglobin in these cells may enable the "storage of oxygen to provide a homeostatic mechanism in anoxic conditions, which is especially important for A9 DA neurons that have an elevated metabolism with a high requirement for energy production". It has been noted further that "A9 dopaminergic neurons may be at particular risk of anoxic degeneration since in addition to their high mitochondrial activity they are under intense oxidative stress caused by the production of hydrogen peroxide via autoxidation and/or monoamine oxidase (MAO)-mediated deamination of dopamine and the subsequent reaction of accessible ferrous iron to generate highly toxic hydroxyl radicals". This may explain the risk of degeneration of these cells in Parkinson's disease. The hemoglobin-derived iron in these cells is not the cause of the post-mortem darkness of these cells (origin of the Latin name, substantia nigra), but rather is due to neuromelanin. Outside the brain, hemoglobin has non-oxygen-carrying functions as an antioxidant and a regulator of iron metabolism in macrophages, alveolar cells, and mesangial cells in the kidney.
==== China ==== In 2003, Taco Bell entered the Chinese market by opening a restaurant in the Shanghai People's Square, named "Taco Bell Grande". Three more TBG restaurants opened before they were closed in 2008. Taco Bell relaunched in the Chinese market when a store opened in Pudong, Shanghai, in late 2016. As of March 2024, Taco Bell has 90 outlets in China.
Sources: en.wikipedia.org
In 1977, Migita published further work on the coupling of allyl-tin reagents with both aryl (C) and acyl (D) halides. The greater ability of allyl groups to migrate to the palladium catalyst allowed the reactions to be performed at lower temperatures. Yields for aryl halides ranged from 4% to 100%, and for acyl halides from 27% to 86%. Reflecting the early contributions of Migita and Kosugi, the Stille reaction is sometimes called the Migita–Kosugi–Stille coupling.
A similar promotion was held in September 2011, near the start of a traditional school year, encouraging the use of the game as an educational tool for science and mathematics. Valve wrote that they felt that Portal "makes physics, math, logic, spatial reasoning, probability, and problem-solving interesting, cool, and fun", a necessary feature to draw children into learning. This was tied to Digital Promise, a United States Department of Education initiative to help develop digital tools for education, which Valve is part of. Portal: Still Alive was announced for Xbox Live Arcade at the 2008 E3 convention, and was released on October 22, 2008. It features the original game, 14 new challenges, and new achievements. The additional content was based on levels from the map pack Portal: The Flash Version created by We Create Stuff and contains no additional story-related levels. According to Valve spokesman Doug Lombardi, Microsoft had previously rejected Portal on the platform due to its large size. Portal: Still Alive was well received by reviewers. 1UP.com's Andrew Hayward stated that, with the easier access and lower cost than paying for The Orange Box, Portal is now "stronger than ever". IGN editor Cam Shea ranked it fifth on his top 10 list of Xbox Live Arcade games. He stated that it was debatable whether an owner of The Orange Box should purchase this, as its added levels do not add to the plot. However, he praised the quality of the new maps included. The game ranked 7th in a later list of top Xbox Live Arcade titles compiled by IGN's staff in September 2010.
Beyond its structural effects, intracrine Ang II has been shown to alter cardiac electrical conductivity, increasing the risk of arrhythmias. Intracellular dialysis of Ang II in cardiomyocytes has been observed to reduce junctional conductance and alter calcium signaling, which may contribute to the development of atrial fibrillation and other arrhythmias in conditions such as heart failure. Additionally, the ability of intracrine Ang II to modulate gap junctions and ion channels highlights its potential role in electrical remodeling of the heart. This mechanism may underlie the persistent electrical abnormalities seen in pathological cardiac conditions.
And here is The Mystery of the Yellow Room. That - ah, that is really a classic! I approve of it from start to finish. Such a logical approach! There were criticisms of it, I remember, which said it was unfair. But it is not unfair, my dear Colin. No, no. Very nearly so, perhaps, but no not quite. There is the hair's breadth of difference. No. All through there is truth, concealed with a careful and cunning use of words. Everything should be clear at that supreme moment when the men meet at the angle of the three corridors." He laid it down reverently. "Definitely a masterpiece, and, I gather, almost forgotten nowadays. In a 1981 poll by Edward D. Hoch of 17 mystery writers and reviewers, this novel was voted the third-best locked-room mystery of all time, behind Hake Talbot's Rim of the Pit (1944) and John Dickson Carr's The Hollow Man (1935). The popular 1946 Japanese detective novel The Honjin Murders (本陣殺人事件, Honjin satsujin jiken) by Seishi Yokomizo refers to The Mystery of the Yellow Room numerous times, the narrator quipping that Leroux's novel "bears the closest resemblance" to the story recounted in the novel. The final episode of the 2025 Netflix miniseries The Residence is titled The Mystery of the Yellow Room and concludes the series with a locked-room murder deduction.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.